[go: up one dir, main page]

YU48607B - Transdermalni terapeutski sistem (tts) za odavanje galantamina - Google Patents

Transdermalni terapeutski sistem (tts) za odavanje galantamina

Info

Publication number
YU48607B
YU48607B YU2694A YU2694A YU48607B YU 48607 B YU48607 B YU 48607B YU 2694 A YU2694 A YU 2694A YU 2694 A YU2694 A YU 2694A YU 48607 B YU48607 B YU 48607B
Authority
YU
Yugoslavia
Prior art keywords
tts
therapy system
galantamine
transdermal therapy
administration
Prior art date
Application number
YU2694A
Other languages
English (en)
Other versions
YU2694A (sh
Inventor
Thomas Hille
Lothar Deurer
Original Assignee
Lts Lohmann Therapie-Systeme Gmbh. & Co. Kg.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lts Lohmann Therapie-Systeme Gmbh. & Co. Kg. filed Critical Lts Lohmann Therapie-Systeme Gmbh. & Co. Kg.
Publication of YU2694A publication Critical patent/YU2694A/sh
Publication of YU48607B publication Critical patent/YU48607B/sh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Transdermalni terapeutski sistem (TTS) za odavanje galantamina na kožu, sa jednim zadnjim slojem nepropustljivim za aktivnu supstancu i jednim adhezivnim lepljivim rezervoarskim slojem, naznačen time, što rezervoarski sloj obuhvata 40-80 mas.% polimernog materijala, odabranog iz grupe poliakrilata, 0,1-30 mas. % omekšivača i 0,1-30 mas. % galaktamin baze ili jedne njegove farmaceutski prihvatljive soli. - Prijava sadrži još 7 zavisnih zahteva.
YU2694A 1993-01-23 1994-01-21 Transdermalni terapeutski sistem (tts) za odavanje galantamina YU48607B (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4301783A DE4301783C1 (de) 1993-01-23 1993-01-23 Transdermales therapeutisches System mit Galanthamin als wirksamem Bestandteil

Publications (2)

Publication Number Publication Date
YU2694A YU2694A (sh) 1996-10-18
YU48607B true YU48607B (sh) 1998-12-23

Family

ID=6478781

Family Applications (1)

Application Number Title Priority Date Filing Date
YU2694A YU48607B (sh) 1993-01-23 1994-01-21 Transdermalni terapeutski sistem (tts) za odavanje galantamina

Country Status (26)

Country Link
US (1) US5700480A (sh)
EP (1) EP0680325B1 (sh)
JP (1) JPH08505632A (sh)
KR (1) KR100300477B1 (sh)
AT (1) ATE216240T1 (sh)
AU (1) AU679032B2 (sh)
CA (1) CA2153572C (sh)
CZ (1) CZ287053B6 (sh)
DE (2) DE4301783C1 (sh)
DK (1) DK0680325T3 (sh)
ES (1) ES2176234T3 (sh)
FI (1) FI113744B (sh)
HR (1) HRP940028B1 (sh)
HU (1) HU221165B1 (sh)
IL (1) IL108235A (sh)
MY (1) MY109926A (sh)
NO (1) NO307497B1 (sh)
NZ (1) NZ259857A (sh)
PH (1) PH31473A (sh)
PL (1) PL175083B1 (sh)
PT (1) PT680325E (sh)
SI (1) SI9400024A (sh)
SK (1) SK281339B6 (sh)
WO (1) WO1994016707A1 (sh)
YU (1) YU48607B (sh)
ZA (1) ZA94414B (sh)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4429791C2 (de) * 1994-08-23 1997-04-24 Lohmann Therapie Syst Lts Medizinischer Haftkleber auf Basis von Polyacrylaten und dessen Verwendung
DE19509663A1 (de) * 1995-03-17 1996-09-19 Lohmann Therapie Syst Lts Verfahren zur Isolierung von Galanthamin
AU732803B2 (en) * 1996-01-17 2001-05-03 National Starch And Chemical Investment Holding Corporation Adhesives resistant to skin-penetration enhancers
AT402691B (de) * 1996-01-26 1997-07-25 Sanochemia Ltd Verwendung von galanthamin zum herstellen von arzneimitteln zur behandlung von trisomie 21 oder verwandter trisomie-syndrome
US6512010B1 (en) 1996-07-15 2003-01-28 Alza Corporation Formulations for the administration of fluoxetine
ATE322272T1 (de) * 1996-07-15 2006-04-15 Alza Corp Neue formulierungen zur transdermale verabreichung von fluoxetin
DE19649534B4 (de) * 1996-11-29 2004-05-06 Lts Lohmann Therapie-Systeme Ag Verpackung aus Verbundpackstoff zum Verpacken von wirkstoffhaltigen Pflastern
DE19653605C2 (de) * 1996-12-20 2002-11-28 Roehm Gmbh Haft- und Bindemittel für dermale oder transdermale Therapiesysteme und dessen Verwendung zur Herstellung eines transdermalen Therapiesystems
US6203817B1 (en) 1997-02-19 2001-03-20 Alza Corporation Reduction of skin reactions caused by transdermal drug delivery
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
US6193993B1 (en) * 1998-03-03 2001-02-27 Eisai Co., Ltd. Suppository containing an antidementia medicament
OA11740A (en) * 1998-12-24 2005-05-13 Janssen Pharmaceutica Nv Controlled release galantamine composition.
US6241998B1 (en) 1999-02-02 2001-06-05 Acutek International Dermatological patch
DE19906977C1 (de) * 1999-02-19 2000-06-15 Lohmann Therapie Syst Lts Desoxypeganin-TTS und seine Verwendung
EP1221315A4 (en) * 1999-10-13 2007-12-12 Senju Pharma Co ADHESIVE OPHTHALMIC PREPARATIONS FOR PERCUTANEOUS SPREADING
EP1237524A4 (en) * 1999-12-10 2004-06-30 Bonnie M Davis GALANTHAMINE AND LYCORAMINE ANALOGS FOR USE AS MODULATORS OF NICOTINIC RECEPTORS
AU5882801A (en) * 2000-05-26 2001-12-03 Sumitomo Pharmaceuticals Company, Limited Novel recombinant adenovirus vector with relieved side effects
FR2814368B1 (fr) * 2000-09-26 2004-05-07 Pf Medicament Preparation pharmaceutique a base d'oxans
DE10141652B4 (de) * 2001-08-24 2011-04-07 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System auf der Basis von Polyacrylat-Haftklebern ohne funktionelle Gruppen und seine Verwendung
DE10235556A1 (de) * 2002-08-03 2004-02-19 Hf Arzneimittelforschung Gmbh Medikament und Verfahren zur Verringerung des Alkohol- und/oder Tabakkonsums
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
EP1763337A2 (en) * 2003-12-31 2007-03-21 Actavis Group HF Immediate, controlled and sustained release formulations of galanthamine
CA2552114A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Solid dosage formulations of galantamine
AT500143A1 (de) * 2004-04-22 2005-11-15 Sanochemia Pharmazeutika Ag Cholinesterase-inhibitoren in liposomen sowie deren herstellung und verwendung
WO2006124585A2 (en) 2005-05-13 2006-11-23 Alza Corporation Multilayer drug system for the delivery of galantamine
WO2007035941A2 (en) * 2005-09-23 2007-03-29 Alza Corporation Transdermal galantamine delivery system
TWI389709B (zh) * 2005-12-01 2013-03-21 Novartis Ag 經皮治療系統
DE102008059054A1 (de) 2008-11-26 2010-05-27 Otto Bock Pur Life Science Gmbh Polyurethanpflaster für die transdermale Applikation von Wirkstoffen und Verfahren zu dessen Herstellung
US9844515B2 (en) 2010-11-17 2017-12-19 Hexal Ag Transdermal therapeutic system comprising buprenorphine
KR101317158B1 (ko) 2011-02-18 2013-10-15 조선대학교산학협력단 갈란타민 또는 그의 염을 함유하는 경피흡수제제
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
ES2885523T3 (es) 2011-11-23 2021-12-14 Therapeuticsmd Inc Formulaciones y terapias de reposición hormonal de combinación naturales
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
AR100562A1 (es) 2014-05-22 2016-10-12 Therapeuticsmd Inc Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
JP6285820B2 (ja) * 2014-08-07 2018-02-28 久光製薬株式会社 ガランタミン含有経皮吸収製剤
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
CA3020153A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US20180008612A1 (en) * 2016-07-11 2018-01-11 Taho Pharmaceuticals Ltd. Transdermal delivery system containing galantamine or salts thereof
CN114615974B (zh) 2019-11-06 2025-01-03 智能科技专题有限公司 环加氧酶抑制剂的局部制剂及其用途
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU560710B2 (en) * 1983-04-27 1987-04-16 Lohmann Gmbh & Co. Kg. Pharmaceutical product
US4663318A (en) * 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
DE3843239C1 (sh) * 1988-12-22 1990-02-22 Lohmann Therapie Syst Lts
DE4010079A1 (de) * 1990-03-29 1991-10-02 Lohmann Therapie Syst Lts Pharmazeutische formulierung zur behandlung des alkoholismus
DE69229781T2 (de) * 1991-05-14 2000-01-05 Ernir Snorrason Behandlung des ermüdungssyndroms mit cholinesteraseinhibitoren

Also Published As

Publication number Publication date
HRP940028B1 (en) 2000-02-29
HUT72643A (en) 1996-05-28
FI113744B (fi) 2004-06-15
PL175083B1 (pl) 1998-10-30
FI953533L (fi) 1995-07-21
SK281339B6 (sk) 2001-02-12
MY109926A (en) 1997-09-30
PT680325E (pt) 2002-09-30
IL108235A (en) 1996-10-31
NZ259857A (en) 1996-03-26
CA2153572A1 (en) 1994-08-04
ZA94414B (en) 1994-08-31
JPH08505632A (ja) 1996-06-18
KR960700060A (ko) 1996-01-19
KR100300477B1 (ko) 2001-10-22
SK88995A3 (en) 1996-05-08
SI9400024A (en) 1994-09-30
IL108235A0 (en) 1994-04-12
FI953533A0 (fi) 1995-07-21
HU221165B1 (en) 2002-08-28
PL309603A1 (en) 1995-10-30
DE59410103D1 (de) 2002-05-23
CZ287053B6 (en) 2000-08-16
NO952907L (no) 1995-07-21
NO952907D0 (no) 1995-07-21
NO307497B1 (no) 2000-04-17
AU679032B2 (en) 1997-06-19
US5700480A (en) 1997-12-23
HRP940028A2 (en) 1996-06-30
ES2176234T3 (es) 2002-12-01
DK0680325T3 (da) 2002-08-05
EP0680325B1 (de) 2002-04-17
AU5881794A (en) 1994-08-15
CA2153572C (en) 2006-01-03
WO1994016707A1 (de) 1994-08-04
ATE216240T1 (de) 2002-05-15
CZ184295A3 (en) 1996-01-17
DE4301783C1 (de) 1994-02-03
EP0680325A1 (de) 1995-11-08
PH31473A (en) 1998-11-03
YU2694A (sh) 1996-10-18
HU9501928D0 (en) 1995-09-28

Similar Documents

Publication Publication Date Title
YU48607B (sh) Transdermalni terapeutski sistem (tts) za odavanje galantamina
YU47956B (sh) Postupak za izradu transdermalnog terapijskog sistema sa buprenorphinom kao aktivnim sastojkom
ES2152979T3 (es) Sistema terapeutico transdermal que contiene estradiol.
DE59105209D1 (de) Transdermales therapeutisches System mit dem Wirkstoff Tulobuterol.
ZA901183B (en) Therapeutic system for the retarded and controlled transdermal or transmucous administration of active substances
ATE293442T1 (de) Desoxypeganin-tts
YU22894A (sh) Sistemi za kontrolisano davanje pilokarpina
YU48663B (sh) Flaster koji sadrži nitroglicerin i postupak za njegovo dobijanje
YU71293A (sh) Transdermalni terapijski sistem za davanje fizostigmina na koži i postupak za njegovu izradu
YU47075B (sh) Postupak za izradu transdermalnog terapijskog sistema sa noepseudiefedrinom kao aktivnim sastojkom